Arca
Skip to content
Tools
Tools

HCRTR1: Orexin/Hypocretin receptor type 1

G protein-coupled receptor that binds the neuropeptide orexin-A with high affinity, and orexin-B with lower affinity, two peptides derived from a common precursor, prepro-orexin.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on HCRTR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved2

  • Lemborexant
  • Daridorexant

Phase 30

    Phase 21

    • SB-649868

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Orexin receptor 1 antagonist.
      LemborexantApprovedEisaiSmall moleculeAntagonist23
      DaridorexantApprovedIdorsiaSmall moleculeAntagonist16
      SB-649868Phase 2GSKSmall moleculeAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
      Lemborexant on Perioperative Sleep Quality in Patients Undergoing Breast Cancer SurgeryLemborexantPhase 4Not yet recruitingBeijing Tiantan HospitalNov 5, 2026
      Lemborexant on Perioperative Sleep Quality in Patients With Brain Tumor Undergoing SurgeryLemborexantPhase 2Not yet recruitingBeijing Tiantan HospitalOct 29, 2026
      Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain StimulationLemborexantPhase 2Not yet recruitingBeijing Tiantan HospitalOct 29, 2026
      A Multicenter Observational Study of Daridorexant in the Treatment of InsomniaDaridorexant—Not yet recruitingShanghai Mental Health CenterSep 29, 2026
      A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the DayDaridorexantPhase 3RecruitingIdorsia Pharmaceuticals Ltd.Sep 28, 2026
      How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS)LemborexantPhase 4Not yet recruitingUniversity of AlbertaSep 25, 2026
      Daridorexant for Sleep Disturbance in Adults With Liver CirrhosisDaridorexantPhase 4Not yet recruitingWang FengmeiSep 21, 2026
      Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic SurgeryLemborexantPhase 2Not yet recruitingBeijing Tiantan HospitalSep 10, 2026
      Lemborexant for Cannabis Use DisorderLemborexantPhase 1 / Phase 2Not yet recruitingUniversity of CalgarySep 3, 2026
      Study on the Management of COMISADaridorexantNot applicableRecruitingUniversity Hospital, GrenobleAug 4, 2026
      Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients(EASY-TIP)DaridorexantPhase 4Not yet recruitingXuanwu Hospital, BeijingJul 29, 2026
      Daridorexant for People With Insomnia and Alcohol Use Disorder StudyDaridorexantPhase 2Not yet recruitingSterling McPhersonJul 14, 2026
      Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled TrialLemborexantPhase 2Not yet recruitingBeijing Tiantan HospitalJul 10, 2026
      The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal ThresholdLemborexantPhase 1 / Phase 2Not yet recruitingChulalongkorn UniversityJul 6, 2026
      Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and InsomniaDaridorexantPhase 4Not yet recruitingInstitut d'Investigació Biomèdica de BellvitgeApr 29, 2026
      Daridorexant for Alcohol Use DisorderDaridorexantPhase 2Not yet recruitingJohns Hopkins UniversityApr 15, 2026

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Intelligence0.34
      • Alzheimer disease0.30
      • Alcohol dependence0.29
      • Abnormality of serum enzyme levels0.21
      • Abnormality of the skeletal system0.19
      • Obstructive sleep apnea syndrome0.10

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5113, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt O43613, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.